Heartflow Q4 Earnings Call Highlights

Heartflow (NASDAQ:HTFL) executives highlighted record revenue, accelerating adoption of its platform, and expanding reimbursement support during the company’s fourth-quarter 2025 earnings call, while ...

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of ...